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Abstract
The transdermal fentanyl patch is widely used to treat cancer-related pain despite its wide
inter- and intrapatient variability in pharmacokinetics. The aim of this study was to investi-
gate whether smoking and body size (i.e. body mass index) influence fentanyl exposure in
patients with cancer. These are factors that typically change during treatment and disease
trajectories. We performed an explorative cohort study in patients with cancer using trans-
dermal fentanyl patches (Durogesic®), by taking a blood sample for pharmacokinetic
analysis one day after applying a patch in patients with a stable fentanyl dose. A total of 88
patients were evaluable. Although no statistically significant difference was found, the
plasma concentrations of non-smokers was 28% (95% CI [-14%; +89-%]) higher than those
of smokers normalizing for a dose of 25μg/min. Patients with a low BMI (< 20 kg/m2) had
almost similar (10% (95% CI [-39%; +97%]) higher) plasma concentrations compared to
patients with a high BMI (> 25 kg/m2). A wider variation in fentanyl plasma concentrations
was found in this study than anticipated. Due to this variation, studies in larger patient
cohorts are needed to further investigate the effect of smoking on plasma concentration of
fentanyl and thereby clarify the clinical significance of our findings.
Introduction
Fentanyl is one of the most commonly used (strong acting) opioids to treat cancer-related pain
[1–3] and it is often preferred over morphine, especially in patients with renal failure. Addi-
tionally, fentanyl usually results in less obstipation than other opioids [4–6]. The fentanyl
transdermal patch has been used since decades to treat chronic pain. Fentanyl is also available
in a liquid formulation for intravenous and subcutaneous administration and in various
immediate release forms for oromucosal and nasal use [7, 8]. Fentanyl is highly lipophilic and
is therefore rapidly absorbed by the subcutaneous fat-tissue. After placement of the patch
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fentanyl is absorbed by the skin. When the patch is removed systemic fentanyl concentration
will slowly decrease as a result of fentanyl release from subcutaneous depots (formed below the
patch) [7, 9, 10].
Fentanyl is mainly metabolized in the liver by cytochrome P450 (CYP) enzymes, primarily
by the CYP3A4 isozyme into the pharmacologically inactive metabolite norfentanyl by N-deal-
kylation. Fentanyl is mostly excreted by the kidney of which approximately 10% is unchanged.
A minor part is excreted through the feces. There is a wide inter- and intra-patient variability
in fentanyl pharmacokinetics (PK). Several factors have been studied to clarify this variability
in fentanyl pharmacokinetics; liver function, strong CYP3A4 inhibitors and inducers and add-
ing local heat to transdermal patches evidently affect fentanyl pharmacokinetics but only partly
explain the wide variability mentioned [7]. Other unknown factors may also be contributing to
this variation.
Two patient characteristics that may change during various stages of cancer are body size
measures and smoking habits, while their effects on fentanyl exposure in patients with cancer
are currently unknown. The body mass index (BMI) is one of the most commonly used body
size measures and is calculated by weight (in kilogram) divided by the square of height. In
patients with advanced disease a decrease in BMI is common and this may lead to a changed
body composition, changed thickness of the skin, and changed skin permeability. Some studies
already studied the influence of BMI on fentanyl pharmacokinetics with contradictory results.
One study reported that cachectic patients with cancer treated with transdermal fentanyl
patches had significantly lower fentanyl plasma concentrations compared to normal weight
patients [11]. Other studies did not find differences in fentanyl levels between normal weight
and low weight patients with cancer [12, 13].
Smoking is a daily routine for many patients with cancer. If smoking alters fentanyl expo-
sure, a change in smoking habits like (re-)starting or quitting smoking may influence fentanyl
pharmacokinetics and therefore its effects on pain. The polycyclic aromatic hydrocarbons in
cigarette smoke are believed to be responsible for the induction of CYP iso-enzymes [14,
15]. Cigarette smoking was shown to induce drug metabolism in patients using diazepam, hal-
operidol and/or caffeine [16–18]. Furthermore, smoking patients showed a lower exposure to
erlotinib and irinotecan compared to non-smoking patients. Like fentanyl, erlotinib and irino-
tecan are also partly metabolized by CYP3A4 [19, 20]. Therefore, we hypothesized that smok-
ing may have an effect on the exposure of fentanyl.
The aim of this prospective cohort study was to investigate the influence of BMI and smok-
ing on the exposure of fentanyl in patients with cancer using a fentanyl patch.
Methods
Our study was performed as a prospective single-center pharmacokinetic study at the Erasmus
MC Cancer Institute. Patients were included from 1st of April 2014 until 27th of October 2015.
Inclusion criteria were: patients with cancer 18 years, using a stable dose of a transdermal
fentanyl (Durogesic1) for at least 8 days irrespective of the dose used and given written
informed consent. Exclusion criteria were: use of fentanyl rescue medication (other opioids
were allowed), the use of strong CYP inhibitors or inducers and serious psychiatric illness,
confusion or intellectual disability. Smoking was defined as smoking tobacco daily. Non-
smoking patients were defined as patients who had never smoked, or quit smoking at least one
month before PK sampling. Patients were divided in three BMI groups; BMI<20 kg/m2 (low),
BMI 20–25 kg/m2 (normal) and BMI >25 kg/m2 (high). Patients applied the patch to the
upper arm. One venous blood sample was taken from the contralateral arm approximately 24
hours after application of a new patch. The blood samples were collected in potassium EDTA
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coated tubes. Patients were not evaluable when the appropriate blood samples were not taken.
Lab results of levels of creatinine, estimated glomerular filtration rate (eGRF), calculated by
Modification of Diet in Renal Disease (MDRD); [formula: eGFR (ml/min/1.73 m2) = 32788 x
serum Creatinine (μmol/l) -1.154 x age (years) -0.203 x (0.742 when female) x (1.210 when of
African descent)], aspartate aminotransferase (AST), alanine aminotransferase (ALT), biliru-
bin, albumin and alkaline phosphatase (ALP) were assessed. Protocol in S1 Protocol. Trend
statement in S1 Trend.
The study was approved by the medical ethics review board of the Erasmus Medical Center
(MEC 13.412) on the 27th of March 2014 and conducted in accordance with the Declaration of
Helsinki. Written informed consent was obtained from all patients. The trial was registered in
the Dutch Trial Register (Trial registration ID: NTR4672) in July 2014. The authors confirm
that all ongoing and related trials for this drug/intervention are registered.
Measurements of fentanyl plasma concentrations
Fentanyl in plasma was quantitated using a validated UPLC-MS/MS method consisting of a
Waters Acquity UPLC sample manager coupled to a triple quadruple mass spectrometer oper-
ating in the multiple reaction monitoring mode (MRM) with positive ion electrospray ioniza-
tion (Waters, Etten-Leur, The Netherlands). The multiple reaction monitoring transition was
set at 337!188.
Chromatographic separation of fentanyl was achieved on an Acquity UPLC1 BEH C18
1.7 μm 2.1 x 100 mm column eluted at a flow-rate of 0.350 mL/min on a gradient of methanol.
The overall cycle time of the method was 6 minutes. The calibration curves were linear over
the range of 0.1 to 10 ng/mL with the lower limit of quantitation validated at 0.1 ng/mL for
fentanyl. The within and between-run precisions at five tested concentrations, including the
LLQ, were 5.5% and 6.1%, respectively, while the average accuracy ranged from 86.2% to
97.5%. The extraction of 200 μL of plasma involved a deproteinization step with acetone fol-
lowed by a simple liquid extraction with ethyl acetate. The organic phase was evaporated and
subsequently dissolved in 100 μL methanolic solutions, from which aliquots of 10 μL were
injected into the UPLC-MS/MS system.
Statistics
For both the analysis on the effect of smoking and of BMI, a difference in exposure of fenta-
nyl of 25% was judged clinically relevant. The inter-patient relative standard deviation in
fentanyl pharmacokinetics was assumed to be 25%. Because two primary questions were to
be answered, the Bonferroni correction was applied to account for multiple testing, resulting
in a two-sided alpha of 0.025. Given a power of 80%, at least 20 patients were required in
each BMI group (low versus high) to detect a difference based on the Student’s t-test. The
assumption was that 25% of our population smoked. To include 20 smokers approximately
80 patients were needed in total. To compensate for non-evaluable patients (due to missing
samples or other potential reasons) we aimed to include 100 patients.
As fentanyl has linear PK in the dose range used, doses were normalised to a dose of 25 μg/h
for comparisons between patients [21, 22]. As the normalized plasma fentanyl concentrations
turned out to follow a log-normal distribution, analyses were performed on the log-trans-
formed concentrations and therefore, results will be presented as geometric means. These take
into account the skewness of the data in contrast to arithmetic means which would have given
unrealistic summary measures of the data. T-tests were performed on log-transformed data to
compare 2 groups; smokers to non-smokers and low-BMI to high-BMI patients with respect
to baseline characteristics. Bonferroni-corrected 95% confidence intervals were obtained by
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constructing 97.5% confidence intervals since the correction means that instead of alpha = 0.05
an alpha of 0.025 needs to be used.
Results
In total, 104 patients were included. Eighty-eight patients (39 males (44%) and 49 females
(56%)) with a median age of 59.5 years (interquartile range (IQR) 53.5–67.0) completed the
study and were evaluable, Fig 1. The demographic data of these evaluable patients are pre-
sented in Table 1. Twenty-seven patients (30.7%) were defined as smokers and 61 patients
(69.3%) as non-smokers. In total, 20 patients had a BMI < 20 kg/m2 (22.7%), 41 patients had a
BMI between 20–25 kg/m2 (46.6%) and 27 patients had a BMI> 25 kg/m2(30.7%). Creatinine,
eGFR, AST, ALT, bilirubin, albumin and ALP turned out to follow a log-normal distribution.
Fig 1. Consort diagram.
https://doi.org/10.1371/journal.pone.0198289.g001
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Only AST levels were significantly lower in smokers compared to non-smokers (p = 0.026),
although this is unlikely to be clinically relevant. All patients had normal or limited (CTCAE
grade 1) toxicities of creatinine, eGFR, AST, ALT, bilirubin, albumin or ALP.
The normalized plasma concentrations of non-smokers and smokers were not statistically
different (p = 0.32). The geometric means of the normalized plasma concentrations were 0.48
ng/ml (95% CI [0.38; 0.61]) for smokers and 0.62 ng/ml (95% CI [0.50; 0.76]) for non- smok-
ers. The normalized plasma concentrations of non-smokers were 27.7% higher than those of
smokers (95% CI [-13.8%; +89.1%], Fig 2).
The normalized plasma concentrations of patients with a low or high BMI were also not
statistically different (0.62 ng/ml (95% CI [0.41; 0.93]) vs 0.56 ng/ ml (95% CI [0.40; 0.79]),
p = 1.00). Plasma concentrations of the low and high BMI groups did also not differ from the
normal BMI group (0.56 ng/ml (95% CI [0.46; 0.68])). The concentration was 9.7% higher
in patients with a low BMI as compared to patients with a high BMI (95% CI [-38.8%; 96.9%])
Fig 3).

















- Male 39 (44) 15 (56) 24 (39) 13 (65) 16 (39) 10 (37)
- Female 49 (56) 12 (44) 37 (61) 7 (35) 25 (61) 17 (63)
Age, years
median and IQR 60 (53–67) 59 (54–66) 60 (53–68) 60 (49–68) 59 (55–65) 62 (53–69)
Height, cm
median and IQR 170 (163–178) 173 (165–181) 169 (163–177) 175 (169–184) 170 (163–178) 167 (163–177)
Weight, kg
median and IQR 66 (60–78) 69 (62–78) 65 (59–78) 54 (51–63) 64 (61–73) 81 (74–96)
Smoking (n, %) 27 (31) 27 (100) 0 (0) 6 (30) 13 (32) 8 (30)
Laboratory results #
(median (IQR)
Creatinine1 66 (55–87) 70 (51–93) 65 (55–87) 59 (45–84) 62 (56–85) 78 (63–91)
MDRD2 88 (65–90) 89 (65–90) 87 (63–90) 90 (85–90) 90 (66–90) 71 (61–90)
AST3 27 (20–42) 22 (17–31) 30 (22–47) 22 (17–32) 28 (22–50) 31 (19–44)
ALT4 23 (13–34) 23 (13–27) 23 (15–40) 18 (14–27) 23 (13–34) 24 (13–45)
Bilirubin5 6 (4–8) 5 (4–8) 6 (4–8) 4 (3–7) 6 (4–8) 7 (5–9)
Albumin6 39 (36–43) 38 (35–42) 39 (37–44) 38 (32–42) 39 (36–43) 40 (37–44)
ALP7 114 (87–179) 93 (84–165) 124 (90–192) 108 (89–148) 118 (86–214) 111 (83–183)
Fentanyl patch dose (μg/h)
median(IQR) 25 (12–50) 25 (12–50) 25 (12–50) 37 (15–50) 37 (12–69) 25 (12–25)
# Normal ranges:
1 (55–90 umol/L);
2 (> 60 mL/min/1,73 m2);
3 (< 31 U/L);
4 (< 34 U/L);
5 (<17 umol/L);
6 (35–50 g/L);
7 (< 98 U/L)
https://doi.org/10.1371/journal.pone.0198289.t001
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Discussion
Interestingly, in this study, the interindividual variation in plasma fentanyl levels (geometric
coefficient of variation = 87%) was much larger than our original assumption. Consequently,
our study was underpowered to find a statistically significant difference in fentanyl plasma
concentration. Nonetheless, based on our findings, the 27.7% higher normalized plasma con-
centrations of non-smokers compared to smokers, we cannot exclude an effect of smoking
on fentanyl exposure. Smoking is a factor that frequently changes during phases of disease in
patients with cancer. Together with the hypothesis that smoking leads to induction of CYP3A4
[20, 23] and that fentanyl metabolism might also be influenced by other (unknown) metabolic
pathways [24, 25] it might be interesting to study smoking in a larger cohort of patients with
cancer. Nevertheless, other strong inducers like rifampicin [26] and carbamazepine or pheno-
barbital [24] had highly relevant inductive effects on fentanyl PK. The combination of rifampi-
cin and oral transmucosal fentanyl citrate led to a significant lower exposure to fentanyl
compared to fentanyl alone (2.20 vs 5.87 ng/mL). A population pharmacokinetic analysis
showed a significantly higher fentanyl clearance when patients used CYP3A4 inducers com-
pared to patients who did not use CYP3A4 inducers [24].
Fig 2. Normalized plasma fentanyl concentrations in patients; smokers and non-smokers. Horizontal line
represents the median.
https://doi.org/10.1371/journal.pone.0198289.g002
Effects of smoking and body mass index on the exposure of fentanyl in patients with cancer
PLOS ONE | https://doi.org/10.1371/journal.pone.0198289 June 8, 2018 6 / 10
Unfortunately our study lacks information about the daily consumption of cigarettes and
its use over the years. Probably, the amount of cigarettes smoked daily influences the size of
enzyme induction. All patients who were included in the non-smoking group did not smoke
for at least one month before inclusion. The time to require maximum enzyme induction
takes approximately two weeks [20, 23]. We therefore assume that potential late effects of
enzyme induction by cigarette smoking were ruled out in this study since a minimum period
of 4 weeks without smoking was required to be eligible for the non-smoking group.
Transdermal fentanyl is absorbed by the skin and a fentanyl depot concentrates in the
upper skin layers. This is followed by uptake in the microcirculation and general circulation.
Skin conditions of smokers are different compared to non-smokers; skin ageing is accelerated
and leads to reduced functional capacity of the skin causing dryness of the skin and wrinkles
[27–29]. This reduced skin condition might affect transdermal absorption of fentanyl. A limi-
tation of this study is that we did not specify the skin conditions of the patients in this study
and the sampling design did not allow us to describe the absorption phase. BMI did not signifi-
cantly influence the exposure to transdermal fentanyl in our cohort of patients, which is in line
with earlier studies [12, 13]. Hypoalbuminemia is common in patients with a low BMI and
because of the lipophilic character of fentanyl, the binding of fentanyl to plasma proteins like
albumin might be influenced by the plasma concentration of albumin [7, 12]. In our study, the
Fig 3. Normalized plasma fentanyl concentrations in patients; low, middle and high BMI patients. Horizontal line represents the
median.
https://doi.org/10.1371/journal.pone.0198289.g003
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albumin levels were within normal ranges and comparable in all BMI groups. The combina-
tion of low BMI and normal albumin did not influence fentanyl plasma concentration in
another study [12]. Only a study by Heiskanen et al. showed significantly lower plasma fenta-
nyl levels in cachectic patients with cancer compared to normal weight patients [11]. Probably
this is due to the extremely low BMI group of< 16 in their study. An explanation for their
finding might be lower skinfold thickness in cachectic patients. The thinner lipophilic part of
the skin possibly impairs the absorption of lipophilic fentanyl [9]. Possibly, other factors, not
studied, related to BMI and cachexia like CRP, skinfold and skin condition might also influ-
ence absorption.
In summary, we conducted a prospective cohort study to investigate the influence of smok-
ing or BMI on plasma fentanyl concentrations. For both factors we did not find any evidence
for an effect nor the lack of an effect. This study was underpowered because of unexpectedly
large variations in fentanyl levels between patients. To study the effect of smoking and BMI on
fentanyl levels a larger patient population needs to be tested.
Supporting information
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(DOC)
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